Patients with mitral and tricuspid heart valve disease often have complex conditions with limited treatment options. Our Transcatheter Mitral and Tricuspid Therapies (TMTT) business unit is boldly pursuing an innovative portfolio of technologies to address a patient’s unmet clinical needs. It’s our driving force to help patients live longer and healthier lives. Join us and be part of our inspiring journey.
Since 2017, Edwards TMTT launched more than 4 products – transformational therapies in Europe led by its PASCAL and EVOQUE programs. Every patient is different - be an expert on our **EVOQUE** device / therapy and help patients suffering from mitral and tricuspid diseases!
**The Field Clinical Specialist** is responsible for educating physicians on EVOQUE technologies, device handling, implantation and troubleshooting techniques and case support by assigned hospitals / in assigned territories / regions.